Investigation of Serum PIVKA-II Levels in Patients with Helicobacter pylori Infection and Normal Group

Document Type : Research/Original Article


1 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran


Background: Helicobacter pylori is a highly prevalent microorganism and risk factor for gastric cancer. In this study, we evaluated the serum levels of PIVKA-II in patients with and without H. pylori.
Methods: This study was performed on 90 patients (45 with H. pylori infection and 45 in the control group). After recording demographic information, serum levels of PIVKA-II were measured by the ELISA method.
Results: We found no significant difference in PIVKA-II levels between all patients with and without H. pylori infection (P=0.08), but among individuals aged below 40 years old, H. pylori infection was associated with significantly lower serum PIVKA levels in patients vs. controls (P=0.026). Among men, H. pylori infection was associated with a significantly lower serum PIVKA level than controls (P=0.038). Among all H. pylori-infected patients, women had higher PIVKA levels than men (P=0.037).
Conclusion: Our results indicate that (i) serum PIVKA-II levels are lower in H. pylori-infected individuals under 40 years old and men than in non-infected controls, and ii) among all H. pylori-infected patients, serum PIVKA-II levels are lower in men than women and in those under 40 years of age compared to those 40 or above. 


  1. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. The Lancet. 2008;372(9636):392-7.
  2. Holleczek B, Schöttker B, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: results from the prospective population‐based ESTHER cohort study. International journal of cancer. 2020;146(10):2773-83.
  3. Wu M-S, Chen C-J, Lin J-T. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiology Biomarkers & Prevention. 2005;14(8):1878-82.
  4. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European journal of cancer. 2018;103:356-87.
  5. Tartaglione S, Pecorella I, Zarrillo SR, Granato T, Viggiani V, Manganaro L, et al. Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study. Biochemia Medica. 2019;29(2):352-8.
  6. Furie B, Furie BC. Molecular basis of vitamin K-dependent γ-carboxylation. Blood. 1990;75(9):1753-62.
  7. Kim J-H, Jun K-H, Jung H, Park I-S, Chin H-M. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer. Hepato-gastroenterology. 2014;61(131):863-9.
  8. Yang A-P, Liu J, Lei H-Y, Zhang Q-W, Zhao L, Yang G-H. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer. Clinica chimica acta. 2014;437:183-6.
  9. Ishii T, Ozasa R, Miyajima N, Bann N, Hirata Y, Ishidate T, et al. A case of AFP and PIVKA-II producing gastric carcinoma forming a massive tumor embolus in the portal vein. Nihon Shokakibyo Gakkai Zasshi=The Japanese Journal of Gastro-enterology. 2002;99(3):275-81.
  10. Tanaka H, Ishii S, Akutsu N, Ohashi H, Tokuno T, Suzuki T, et al. A case of AFP and PIVKA-II producing gastric carcinoma. Nihon Shokakibyo Gakkai Zasshi=The Japanese Journal of Gastro-enterology. 2006;103(4):426-31.
  11. Takano S, Honda I, Watanabe S, Soda H, Nagata M, Hoshino I, et al. PIVKA-II-producing advanced gastric cancer. International Journal of Clinical Oncology. 2004;9:330-3.
  12. Okuse C, Yotsuyanagi H, Takahashi Y, Hayashi T, Suzuki M, Iino S, et al. Gastric cancer with liver metastasis producing alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II); a case report. Nihon Shokakibyo Gakkai Zasshi=The Japanese Journal of Gastro-enterology. 2003;100(1):28-34.
  13. Takahashi Y, Inoue T, Fukusato T. Protein induced by vitamin K absence or antagonist II-producing gastric cancer. World Journal of Gastrointestinal Pathophysiology. 2010;1(4):129.
  14. Iso Y, Sawada T, Shimoda M, Rokkaku K, Ohkura Y, Kubota K. Solitary AFP-and PIVKA-II-producing hepatoid gastric cancer with giant lymph node metastasis. Hepato-gastroenterology. 2005;52(66):1930-2.
  15. Kucera R, Smid D, Topolcan O, Karlikova M, Fiala O, Slouka D, et al. Searching for new biomarkers and the use of multivariate analysis in gastric cancer diagnostics. Anticancer Research. 2016;36(4):1967-71.
  16. Lim TS, Kim YJ, Kim H, Jeon WJ, Kim JD, Park HW, et al.. Gastric Hepatoid Adenocarcinoma with Increased Serum Levels of Alpha-Fetoprotein and Prothrombin Induced by Vitamin K Absence Ii in Patient with Chronic Liver Disease. (Korean Society of Internal Medicine). 2014;2014(1):255.
  17. Takahashi Y, Inoue T. Des‐γ carboxy prothrombin (PIVKA‐II) and α‐fetoprotein producing gastric cancer with multiple liver metastases. Pathology international. 2003;53(4):236-40.